Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 94.35
-3.85 (-3.92%)
Sep 10, 2026, 4:08 PM HKT
Innovent Biologics Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 15,706 | 13,042 | 9,422 | 6,206 | 4,556 | 4,270 |
Revenue Growth | 20.43% | 38.42% | 51.82% | 36.21% | 6.71% | 11.08% |
Gross Profit Gross Profit Growth | 11,946 | 9,998 | 7,163 | 4,399 | 3,175 | 3,045 |
Operating Income Operating Income Growth | 1,094 | 733.62 | -123.3 | -1,564 | -3,123 | -2,703 |
Net Income Net Income Growth | 1,232 | 813.57 | -94.63 | -1,028 | -2,179 | -2,729 |
Earnings Per Share EPS Growth | 0.70 | 0.47 | -0.06 | -0.66 | -1.46 | -1.88 |
EPS Growth | 48.06% | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
The People's Republic of China (PRC) The People's Republic of China (PRC) Growth | 15,104 | 12,069 | 8,983 | 5,753 | 4,133 | 3,968 |
United States of America ("USA") United States of America ("USA") Growth | 343.31 | 380.61 | 411.59 | 442.6 | 411.03 | 261.64 |
Europe Europe Growth | 20.46 | 571.81 | - | - | - | - |
Other Other Growth | - | 19.63 | 26.88 | 10.12 | 12.81 | - |
Total Total Growth | 15,706 | 13,042 | 9,422 | 6,206 | 4,556 | 4,270 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 20,003 | 18,231 | 7,884 | 10,970 | 9,166 | 9,015 |
Total Debt Total Debt Growth | 2,323 | 2,816 | 2,831 | 3,621 | 3,229 | 2,497 |
Net Cash (Debt) Net Cash Growth | 17,680 | 15,416 | 5,053 | 7,349 | 5,938 | 6,518 |
Net Cash Growth | 14.69% | 205.10% | -31.25% | 23.77% | -8.91% | -5.73% |
Net Cash Per Share Net Cash Per Share Growth | 9.85 | 8.85 | 3.10 | 4.71 | 3.98 | 4.48 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | - | 10,001 | 1,287 | 147.81 | -1,919 | -2,025 |
Capital Expenditures CapEx Growth | - | -269.88 | -965.67 | -1,119 | -896.9 | -1,066 |
Free Cash Flow Free Cash Flow Growth | - | 9,731 | 321.36 | -971.58 | -2,816 | -3,090 |
Free Cash Flow Growth | - | 2928.12% | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 76.06% | 76.66% | 76.03% | 70.89% | 69.67% | 71.32% |
Operating Margin | 6.97% | 5.63% | -1.31% | -25.20% | -68.54% | -63.31% |
Pretax Margin | 9.89% | 6.43% | -0.83% | -18.44% | -47.64% | -61.87% |
Profit Margin | 7.85% | 6.24% | -1.00% | -16.56% | -47.83% | -63.91% |
FCF Margin | - | 74.62% | 3.41% | -15.65% | -61.80% | -72.38% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 117.44 | 146.09 | - | - | - | - |
Forward PE | 45.18 | 42.67 | - | - | - | - |
P/FCF Ratio | - | 12.21 | 175.32 | - | - | - |
PS Ratio | 9.06 | 9.11 | 5.98 | 10.14 | 9.98 | 13.46 |